Navigation Links
CyVek, Inc. Secures $5.5 Million in Series D Financing
Date:2/4/2013

WALLINGFORD, Conn., Feb. 4, 2013 /PRNewswire/ -- CyVek, Inc., an innovator in multi-analyte immunoassay technology, announced today that it has secured a Series D round of financing in the amount of $5.5 million.  Connecticut Innovations and a group of private investors participated in the round.

The Series D funding enables the company to create the infrastructure needed to commercialize its novel immunoassay technology, CyPlex™, an integrated test system which includes a proprietary microfluidic cartridge that allows the analysis of multiple biomarkers from very small amounts of biological samples.  This technology has broad appeal in research and clinical applications.  Initially the CyVek system will be used in biomarker analysis in life sciences, drug discovery and clinical research.  CyVek is currently in the beta testing phase.

Per Hellsund , CyVek founder, President and CEO, commented, "We are very pleased to have closed our Series D financing. The funding provided by our investors will enable us to complete development related activities and put together the team and infrastructure required to commercialize.  CyPlex™ continues to demonstrate excellent reproducibility coupled with unprecedented ease of use and will provide exceptional value to researchers and clinicians alike.  We have had extremely positive feedback from early customers and this validates our vision of CyVek fulfilling unmet needs in basic research, translational research and clinical diagnostics."

CyVek was formed in 2010 and is led by an experienced team of researchers and business executives who have developed and commercialized technologies, launched products, driven sales, negotiated partnerships, and led companies from start up to liquidity events.

About CyVek Inc.

CyVek is a privately funded biotechnology company dedicated to the advancement of healthcare by empowering researchers and clinicians with a disruptive technology for performing multi-analyte immunoassays.  CyVek's  CyPlex™ is a versatile platform that can be quickly and easily configured for diverse applications such as rapid diagnostic tests, multi-sample multi-analyte tests, or routine ELISA-like tests, for use in both research and clinical settings.  For more information about CyVek, please call 203-679-0395 or visit us on the web at www.cyvek.com

Contact:
Sheila Burns
203-679-0395


'/>"/>
SOURCE CyVek, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarantus BioScience Secures an Additional $1.4 Million in Financing Commitments
2. Topokine Therapeutics Secures Financing from Schooner Capital to Advance Clinical Development of XAF5 Gel
3. Unisense FertiliTech A/S Secures 24 Million USD in New Capital Investment
4. Biomatrica Secures Financing of $5 Million
5. SurgiQuest, Inc. Secures Additional $18.5 Million Funding to Fuel Worldwide Expansion and Commercialization Efforts
6. Zafgen Secures $21 Million in Series D Financing
7. Flexion Therapeutics Secures $20 Million in Series B Financing
8. Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team
9. ROX Medical secures financing and achieves key milestones in providing minimally-invasive approach for treating hypertension
10. BioMotiv Secures $21 million in Initial Funding
11. Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... India , February 5, 2016 ... a new market research report "Fetal (Labor & Delivery) ... & Antepartum), Warmer, Incubator, Pulse Oximeter, Phototherapy/Jaundice Management Devices, ... published by MarketsandMarkets, This report studies the global market ... market is estimated at USD 6.28 Billion in 2015 ...
(Date:2/4/2016)... 2016 For hospitals considering enrollment in the ... in the program, the Health Resources and Services Administration,s ... , Mega-Guidance , could have significant impact on plans ... September 2016. Essential Insights , Daniel ... summarizes the Mega-Guidance,s key proposed changes, including a new ...
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, ... announced it has entered into a settlement agreement ... (SEC) fully resolving the SEC,s investigation into possible ... Under the terms of the settlement agreement, SciClone ... million, including disgorgement, pre-judgment interest and a penalty.  ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air at King ... colors, assortments and packaging. This staple for Valentine’s Day is a must-have, and can ... For Valentine’s Day, not only are long-stem roses available, but also other flower bouquets, ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... stage for new clinical and scientific initiatives have all marked the last 12 ... appointed President and CEO of the nation’s oldest cancer center, Candace S. Johnson, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco ... micro-needling services in their Napa Valley office. The technique utilizes the body’s own ... Dr. Canales and Dr. Furnas, are part of only a select few cosmetic ...
(Date:2/5/2016)... ... ... After years as an active staff surgeon and having served as the director ... transitioned to chief of the Division of Plastic Surgery at what is now known ... began a second three-year term in January of 2016. , The original selection was ...
(Date:2/5/2016)... ... February 05, 2016 , ... In the fourth quarter ... gathered at the La Valencia Hotel in San Diego, California to discuss changes ... the year’s most outstanding franchise, walking away with the coveted David Wright Award ...
Breaking Medicine News(10 mins):